GSK Grabs Rights to Technology That Gets Drugs Across the Blood-Brain Barrier
GSK is licensing an ABL Bio technology yields bispecific antibodies engineered to leverage a certain transmembrane receptor to cross the blood-brain barrier to treat neurodegeneration. GSK is already partnered with Alector, which has monoclonal antibodies in clinical development for Alzheimer’s disease. The post GSK Grabs Rights to Technology That Gets Drugs Across the Blood-Brain Barrier appeared first on MedCity News.

GSK is licensing an ABL Bio technology yields bispecific antibodies engineered to leverage a certain transmembrane receptor to cross the blood-brain barrier to treat neurodegeneration. GSK is already partnered with Alector, which has monoclonal antibodies in clinical development for Alzheimer’s disease.
The post GSK Grabs Rights to Technology That Gets Drugs Across the Blood-Brain Barrier appeared first on MedCity News.